3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
9
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
25
Neoplasm Metastasis
5
Breast Neoplasms
5
Prostatic Neoplasms, Castration-Resistant
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostate Cancer Metastatic
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Preference
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
NSCLC Harboring NRG1 Fusion
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration Resistant Prostate Cancer
1
Metastatic Castrate-Resistant Prostate Cancer
1
Interventions
tildrakizumab
1
sabizabulin
1
enzalutamide
1
Pluvicto
1
N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Metastatic Castration Resistant Prostate Cancer
×
enzalutamide
×
Clear all
NCT03177187
2024-09-26
ACE
Institute of Cancer Research, United Kingdom
Phase 1/2
Terminated
30 enrolled